Compare SGC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGC | NMRA |
|---|---|---|
| Founded | 1920 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.6M | 554.0M |
| IPO Year | 1994 | 2023 |
| Metric | SGC | NMRA |
|---|---|---|
| Price | $10.05 | $2.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $16.00 | $6.57 |
| AVG Volume (30 Days) | 38.4K | ★ 750.9K |
| Earning Date | 03-03-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | N/A | ★ 57.85 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $566,184,000.00 | N/A |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $21.80 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $0.62 |
| 52 Week High | $13.78 | $3.65 |
| Indicator | SGC | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 31.19 |
| Support Level | $9.76 | $1.78 |
| Resistance Level | $10.39 | $2.58 |
| Average True Range (ATR) | 0.32 | 0.19 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 24.74 | 0.00 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.